Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HRS-7085 in Healthy Participants
NCT05638347Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-7085 in inflammatory bowel disease (IBD) (2 cohorts), sponsored by Atridia Pty Ltd. Primary endpoint: Incidence and severity of adverse events at 1 week. Started Dec 2022; status: completed.
02
Drugs
HRS-7085
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05638347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638347.